Author Archives: Jan Paschal

The IPO market is playing the waiting game.  IPO investors are anticipating Anthropic’s blockbuster filing – possibly by the end of the week. The IPO Calendar shows no large IPOs on tap for the week of Oct. 19, 2026. (This is the 39th anniversary of Black Monday.) Two small deals may get priced this week. […]

Jump shot: TCGX Acquisition Corp. II  (TCXB) – a stock-only SPAC – opened at $11.20 – up 12 percent for a gain of $1.20 from its $10.00 price – in its NASDAQ debut today – Friday, Oct. 16, 2026. TCGX Acquisition II priced its SPAC IPO last night – on Thursday night, Oct. 15, 2026 […]

City Therapeutics (CTY), a Phase 1 biotech, upsized its IPO at pricing to 11.11 million shares – up from 9.72 million shares in the prospectus – and priced the deal at $18.00 – the mid-point of its range – to raise $199.98 million on Thursday night, Oct. 15, 2026. Shares of City Therapeutics (CTY) popped […]

Iambic Therapeutics(IAM) priced its IPO at $16.00 – the mid-point – and sold 9.38 million shares – the number in the prospectus – to raise $150 million on Wednesday night, Oct. 14. The Phase I cancer biotech’s stock edged higher in its NASDAQ debut – opening at $16.15 shortly after noon EDT on Thursday, Oct. […]

Iambic Therapeutics (IAM Proposed) and City Therapeutics (CTY Proposed) are in the spotlight this week as the only two deals on the IPO Calendar so far. Both biotechs are set to go public in a year that’s seen a resurgence in the volume of biotech sector IPOs, compared with 2025. This week’s light IPO Calendar […]

City Therapeutics (CTY Proposed) unveiled its IPO’s terms early today – 9.72 million shares at a price range of $17.00 to $19.00 to raise $174.96 million, if priced at the $18.00 mid-point of its range, according to its S-1/A filing dated Oct. 9, 2026. This is a NASDAQ listing. (Please see our IPO Calendar for […]

TRex Bio (TRXB) priced its IPO at $14.00 – the low end of its range – and sold 8.33 million shares – the number in the prospectus – to raise $116.62 million on Thursday night, Oct. 8, 2026. Today –TRex Bio’s stock slipped 50 cents to open at $13.50 – in its NASDAQ debut at […]

Iambic Therapeutics (IAM Proposed), a biotech targeting breast cancer and lung cancer, unveiled the terms for its $150 million IPO early today and launched the deal for pricing next week. The company is offering 9.38 million shares at a price range of $15.00 to $17.00 to raise $150 million, if priced at the $16.00 mid-point […]

TRex Bio (TRXB Proposed), an Eli Lilly-backed biotech, unveiled the terms for its $125 million IPO early today: 8.33 million shares at a price range of $14.00 to $16.00 to raise $124.95 million, if priced at the $15.00 mid-point of its range, according to its S-1 filing dated Oct. 5, 2026. This is a NASDAQ  […]

Accelevation Holdings (ACCV) priced its IPO at $18.00 – $2.00 below range – and sold 30 million shares – the number of shares in the prospectus – to raise $540 million on Tuesday night, Sept. 29, 2026. Of the 30 million shares in the IPO, Accelevation offered 10 million shares and the selling stockholders (the […]